Bitter Pills:Medicines & The Third World Poor | Page 251

86

Dr. Mahler, World Health Forum, 2(1), 1981, op.cit., p.18.

87

Government of Guyana et al., op.cit., p. 1 and annex 1.

88

Provisional Summary Records of the Fourth, Fifth and Sixth Sessions of Committee A on
the Action Programme on Essential Drugs, 10/11 May 1982, WHO, (A35/A/SR/4-6) and
the Resolution on the Action Programme on Essential Drugs adopted by the Thirty-Fifth World
Health Assembly.

89

-

90

UNCTAD Report and recommendations of the workshop on trade and technology policies
in the pharmaceutical sector, Abidjan, Ivory Coast, 12-23 October 1981, UN, 1982.

91

Dr. Oliver Munyaradzi, Minister of Health, text of speech delivered at the Zimbabwe meeting
of Chief Pharmacists of the Africa Region, in Harare, 26 April 1982, ("Press Statement"
358/82/DC) Department of Information, Zimbabwe.

Government of Guyana et al., op.cit., pp.16-17.
WHO (A35/7) April 1982, op.cit.

CHAPTER 10
1

North-South: A Programme for Survival, the Brandl Reporl, Pan Books, 1980.

2

World Health Organisation, United Nations Conference on Trade and Development, United
Nations Children's Fund. Other UN agencies involved in Pharmaceuticals include:
United Nations Development Programme (UNDP), United Nations Action Programme for
Economic Co-operation (UNAPEC), United Centre for Transnational Corporations
(UNCTC). Other international organisations such as the World Bank and Asian Development
Bank are helping to fund drugs projects, for example setting up local production.

3

WHO Regular Budget 1980/1 Total: $477,135,300 United States $115,158,410) (24%) France
26,058,955) W.Germany 34,078,960) Italy 14,518,920) 51.9% of total budget. Japan 38,774,010)
U.K. 19,106,305) Source: WHO, Proposed Programme Budget for the financial period
1982-1983 (PB/82-83), Geneva, 1980, pp.31-37

4

Dr.Mahler: "How often do I still see you misusing its WHO's very limited financial resources
by perpetuating fragmented projects, requesting fellowships that have very little relevance to
your essential manpower needs, and asking for equipment and supplies of marginal utility!"
"Review of the Report of the Director-General on the work of WHO in 1980", Second Plenary
Meeting, Thirty-Fourth World Health Assembly, Geneva, 4-22 May 1981, Verbatim Record
of Plenary Meetings, (WHA34/1981/REC/2) Geneva 1981,p.19

5

Dr. J. F. Dunne, Chief of the Pharmaceuticals Unit, Division of Diagnostic, Therapeutic and
Rehabilitative Technology collects information from member states on regulatory decisions
taken (approving and banning drugs) and compiles these into Drug Information Bulletins.
These are then circulated to health and regulatory authorities worldwide. Unfortunately as
Dr.Dunne is almost a one-person department, these bulletins have been appearing only at
6-monthly intervals.

6

Dr. Mahler was appointed as DG in May 1973, and reappointed in May 1978, (his re-election
is due in 1983). WHO, "Prophylactic and Therapeutic Substances", Report by the DirectorGeneral, Twenty-eighth World Health Assembly, (A28/11) 3 April 1975, p.l.

7

Ibid.,p.2.

S

Catherine Sten/1, Coordinator International Research Group lor Drug Legislation and
Programs, "The Role of International Organisations in Medicines Policy", in Blum,
Herxheimer, Stenzl and Woodcock (ed) Pharmaceuticals and Health Policy, Croom Helm.
London, 1981, p.223.

244